Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MT1013 in CKD and SHPT on Hemodialysis
NCT06690242Phase 2Completed
- Sponsor
- Shaanxi Micot Technology Co., Ltd.
- Start
- Nov 2024
- Primary completion
- Aug 2025
- Modality
- Recombinant Proteins and Enzymes, Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
Phase 2, randomised trial of MT1013 in secondary hyperparathyroidism (SHPT) (4 arms), sponsored by Shaanxi Micot Technology Co., Ltd. Primary endpoint: Percentage of participants with > 30% reduction from baseline in mean intact parathyroid hormone (iPTH). Started Nov 2024; status: completed.
02
Drugs
MT1013
03
Conditions
secondary hyperparathyroidism (SHPT)
Beyond the preview
Go deeper on NCT06690242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06690242.